SI3515490T1 - Protitelesa proti signalno-regulatornem proteinu alfa in načini uporabe - Google Patents

Protitelesa proti signalno-regulatornem proteinu alfa in načini uporabe

Info

Publication number
SI3515490T1
SI3515490T1 SI201731249T SI201731249T SI3515490T1 SI 3515490 T1 SI3515490 T1 SI 3515490T1 SI 201731249 T SI201731249 T SI 201731249T SI 201731249 T SI201731249 T SI 201731249T SI 3515490 T1 SI3515490 T1 SI 3515490T1
Authority
SI
Slovenia
Prior art keywords
methods
antibodies against
regulatory protein
protein alpha
against signal
Prior art date
Application number
SI201731249T
Other languages
English (en)
Slovenian (sl)
Inventor
Jaume Pons
Bang Janet Sim
Hong Wan
Tracy Chia-Chien Kuo
Steven Elliot Kauder
William Don Harriman
Shelley Izquierdo
Original Assignee
ALX Oncology Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ALX Oncology Inc. filed Critical ALX Oncology Inc.
Publication of SI3515490T1 publication Critical patent/SI3515490T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/289—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
SI201731249T 2016-09-21 2017-09-20 Protitelesa proti signalno-regulatornem proteinu alfa in načini uporabe SI3515490T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662397752P 2016-09-21 2016-09-21
US201762515480P 2017-06-05 2017-06-05
PCT/US2017/052592 WO2018057669A1 (en) 2016-09-21 2017-09-20 Antibodies against signal-regulatory protein alpha and methods of use
EP17853838.5A EP3515490B8 (en) 2016-09-21 2017-09-20 Antibodies against signal-regulatory protein alpha and methods of use

Publications (1)

Publication Number Publication Date
SI3515490T1 true SI3515490T1 (sl) 2023-06-30

Family

ID=61689740

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201731249T SI3515490T1 (sl) 2016-09-21 2017-09-20 Protitelesa proti signalno-regulatornem proteinu alfa in načini uporabe

Country Status (33)

Country Link
US (5) US11401338B2 (https=)
EP (2) EP3515490B8 (https=)
JP (3) JP7181874B2 (https=)
KR (1) KR102601298B1 (https=)
CN (3) CN109862915B (https=)
AU (1) AU2017332285B2 (https=)
BR (1) BR112019003027A2 (https=)
CA (1) CA3034480A1 (https=)
CL (2) CL2019000668A1 (https=)
CO (1) CO2019003809A2 (https=)
DK (1) DK3515490T3 (https=)
ES (1) ES2932602T3 (https=)
GE (4) GEP20237528B (https=)
HR (1) HRP20221323T1 (https=)
HU (1) HUE060170T2 (https=)
IL (2) IL297891B2 (https=)
JO (1) JOP20190009A1 (https=)
LT (1) LT3515490T (https=)
MA (1) MA46290A (https=)
MX (1) MX2019003168A (https=)
MY (1) MY197854A (https=)
PE (1) PE20190575A1 (https=)
PH (1) PH12019500600A1 (https=)
PL (1) PL3515490T3 (https=)
PT (1) PT3515490T (https=)
RS (1) RS63658B1 (https=)
SA (1) SA519401371B1 (https=)
SG (1) SG10201912878UA (https=)
SI (1) SI3515490T1 (https=)
SM (1) SMT202200426T1 (https=)
UA (1) UA126281C2 (https=)
WO (1) WO2018057669A1 (https=)
ZA (1) ZA201900937B (https=)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
WO2017027422A1 (en) 2015-08-07 2017-02-16 Alexo Therapeutics Inc. Constructs having a sirp-alpha domain or variant thereof
RS66062B1 (sr) 2016-04-14 2024-11-29 Ose Immunotherapeutics Nova anti-sirpa antitela i njihove terapijske primene
JOP20190009A1 (ar) 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
CN118027200A (zh) 2016-12-09 2024-05-14 艾利妥 抗SIRPα抗体及其使用方法
JP7179743B2 (ja) * 2017-02-17 2022-11-29 オーエスイー・イミュノセラピューティクス 抗ＳＩＲＰｇ抗体の新規の使用
CN118267470A (zh) 2017-04-13 2024-07-02 赛罗帕私人有限公司 抗SIRPα抗体
MX2019012295A (es) 2017-04-14 2020-02-07 Tollnine Inc Polinucleotidos inmunomoduladores, conjugados de anticuerpos de los mismos y metodos para su uso.
JP7262440B2 (ja) 2017-08-02 2023-04-21 フェインズ セラピューティクス，インコーポレーテッド 抗ｃｄ４７抗体及びその使用
MX2020009774A (es) * 2018-03-21 2020-10-08 Alx Oncology Inc Anticuerpos contra proteína alfa reguladora de señal y métodos de uso.
AU2018418224B2 (en) * 2018-04-09 2025-04-17 Oricell Therapeutics Co., Ltd. Anti-PD-L1 antibody and use thereof
CA3097193A1 (en) * 2018-05-08 2019-11-14 Phanes Therapeutics, Inc. Anti-dll3 antibodies and uses thereof
EP3802602A1 (en) * 2018-05-25 2021-04-14 Alector LLC Anti-sirpa antibodies and methods of use thereof
CN110577597B (zh) * 2018-06-11 2021-10-22 康诺亚生物医药科技（成都）有限公司 一种阻断CD47和SIRPα相互作用的抗体
KR20250079073A (ko) 2018-07-10 2025-06-04 고쿠리츠다이가쿠호진 고베다이가쿠 항 SIRPα 항체
WO2020033646A1 (en) * 2018-08-08 2020-02-13 Orionis Biosciences, Inc. SIRP1α TARGETED CHIMERIC PROTEINS AND USES THEREOF
CN110878123B (zh) * 2018-09-05 2022-08-23 华瑞同康生物技术（深圳）有限公司 一种抗tk1原核重组单链抗体及制备方法
US11591390B2 (en) 2018-09-27 2023-02-28 Celgene Corporation SIRP-α binding proteins and methods of use thereof
SG11202102851XA (en) * 2018-09-27 2021-04-29 Celgene Corp SIRPa BINDING PROTEINS AND METHODS OF USE THEREOF
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
JP7536025B2 (ja) * 2018-10-17 2024-08-19 タラック セラピューティクス，インク． 免疫調節性ポリヌクレオチドコンジュゲートと使用方法
CN113286613A (zh) * 2018-10-29 2021-08-20 Umc乌得勒支控股有限公司 IgA介导的通过中性粒细胞的CD47-SIRPα检查点抑制对异常细胞的杀伤
EP3876977A1 (en) 2018-11-06 2021-09-15 The Regents Of The University Of California Chimeric antigen receptors for phagocytosis
EP3880239A4 (en) * 2018-11-14 2022-11-23 Arch Oncology, Inc. THERAPEUTIC SIRPalpha ANTIBODIES
CA3118966A1 (en) * 2018-11-15 2020-05-22 Byondis B.V. Humanized anti-sirpa antibodies
US20220235144A1 (en) * 2019-03-04 2022-07-28 Qilu Puget Sound Biotherapeutics Corporation Anti-sirp-alpha antibodies
US11013764B2 (en) 2019-04-30 2021-05-25 Myeloid Therapeutics, Inc. Engineered phagocytic receptor compositions and methods of use thereof
BR112021024003A2 (pt) 2019-05-31 2022-04-19 Alx Oncology Inc Métodos de tratamento de câncer com fusão sirp alfa-fc em combinação com um inibidor de checkpoint imunológico
CN114206912B (zh) * 2019-06-07 2025-02-11 Alx肿瘤生物技术公司 用于在血清学测定中减少结合cd47的药物的干扰的方法和试剂
CR20210687A (es) 2019-06-25 2022-03-03 Gilead Sciences Inc PROTEÍNAS DE FUSIÓN FLT3L-Fc Y MÉTODOS DE USO
WO2021003074A1 (en) * 2019-07-03 2021-01-07 Crystal Bioscience Inc. Anti-cd38 antibody and methods of use thereof
US12441802B2 (en) 2019-07-03 2025-10-14 Crystal Bioscience Inc. Anti-B7-H3 antibody and methods of use thereof
KR102236127B1 (ko) 2019-08-08 2021-04-07 주식회사 하울바이오 티로시나아제를 억제하는 항-티로시나아제 항체 및 이의 용도
WO2021032078A1 (en) * 2019-08-20 2021-02-25 Elpiscience (Suzhou) Biopharma, Ltd. Novel anti-sirpa antibodies
JP7831937B2 (ja) 2019-09-03 2026-03-17 クリエイト・メディシンズ，インコーポレーテッド ゲノム組込みのための方法および組成物
CN114555123B (zh) 2019-10-18 2024-04-02 四十七公司 用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法
CN110734897A (zh) * 2019-10-31 2020-01-31 浙江蓝盾药业有限公司 杂交瘤细胞株12g6、抗体及其应用
KR20220091576A (ko) 2019-10-31 2022-06-30 포티 세븐, 인코포레이티드 혈액암의 항-cd47 및 항-cd20 기반 치료
WO2021102173A1 (en) * 2019-11-21 2021-05-27 Unity Biotechnology Antibodies directed to tie-2 and methods of use
AU2020394204A1 (en) 2019-11-27 2022-06-02 ALX Oncology Inc. Combination therapies for treating cancer
US10980836B1 (en) 2019-12-11 2021-04-20 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
JP7437815B2 (ja) * 2019-12-24 2024-02-26 ラノバ メディシンズ リミテッド 抗ＳＩＲＰαモノクローナル抗体およびその使用
LT4081305T (lt) 2019-12-24 2024-11-25 Carna Biosciences, Inc. Diacilglicerolio kinazę moduliuojantys junginiai
TWI869528B (zh) 2020-01-13 2025-01-11 美商威特拉公司 C5ar1抗體分子及其用途
KR20260017503A (ko) 2020-02-14 2026-02-05 길리애드 사이언시즈, 인코포레이티드 Ccr8에 결합하는 항체 및 융합 단백질, 및 이의 용도
BR112022017136A2 (pt) 2020-02-28 2022-10-11 Tallac Therapeutics Inc Conjugação mediada por transglutaminase
KR20210122185A (ko) * 2020-03-31 2021-10-08 웰마커바이오 주식회사 Igsf1에 대한 항체를 유효성분으로 포함하는 암 예방 또는 치료용 약학 조성물 및 이를 이용한 암 치료 방법
US12343377B2 (en) 2020-06-01 2025-07-01 ALX Oncology Inc. Combination therapies comprising a hypomethylation agent for treating cancer
AU2021288440A1 (en) * 2020-06-10 2022-12-22 Crystal Bioscience Inc. Anti-BDNF antibodies and methods of use thereof
WO2022020583A1 (en) * 2020-07-24 2022-01-27 The Board Of Trustees Of The Leland Standford Junior University Compositions and methods for modulation of sirpalpha-mediated signaling
EP4192883A4 (en) * 2020-08-05 2024-12-04 Crystal Bioscience Inc. Anti-tigit antibody and methods of use thereof
TW202219069A (zh) * 2020-09-04 2022-05-16 大陸商江蘇恆瑞醫藥股份有限公司 ＳＩＲＰγ變體及其融合蛋白
CA3197423A1 (en) 2020-11-04 2022-05-12 Daniel Getts Engineered chimeric fusion protein compositions and methods of use thereof
JP7663265B2 (ja) * 2020-11-30 2025-04-16 クレ バイオテクノロジ （シャンハイ） カンパニー リミテッド 抗ＳＩＲＰα抗体またはその抗原結合断片および適用
WO2022120286A1 (en) 2020-12-06 2022-06-09 ALX Oncology Inc. Multimers for reducing the interference of drugs that bind cd47 in serological assays
CN112574310B (zh) * 2020-12-11 2023-05-05 浙江博锐生物制药有限公司 抗SIRPα抗体及其用途
EP4308133A4 (en) 2021-03-17 2025-01-22 Myeloid Therapeutics, Inc. MANIPULATED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
AU2022272235A1 (en) 2021-05-11 2023-12-21 Create Medicines, Inc. Methods and compositions for genomic integration
JP2024520902A (ja) 2021-05-13 2024-05-27 エーエルエックス オンコロジー インコーポレイテッド がんを治療するための併用療法
TW202313094A (zh) 2021-05-18 2023-04-01 美商基利科學股份有限公司 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法
BR112023025194A2 (pt) 2021-06-04 2024-02-27 Boehringer Ingelheim Int Anticorpos anti-sirp-alfa
KR20240005901A (ko) 2021-06-23 2024-01-12 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
CA3222277A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271659A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271677A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
JP2024527551A (ja) 2021-06-29 2024-07-25 シージェン インコーポレイテッド 非フコシル化抗ｃｄ７０抗体及びｃｄ４７アンタゴニストの組み合わせを用いるがんを処置する方法
WO2023010076A1 (en) * 2021-07-30 2023-02-02 Alector Llc Anti-sirp-alpha antibodies and methods of use thereof
WO2023020459A1 (zh) 2021-08-17 2023-02-23 杭州九源基因工程有限公司 靶向SIRPα的单克隆抗体及其用途
US20230183216A1 (en) 2021-10-28 2023-06-15 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
EP4422756A1 (en) 2021-10-29 2024-09-04 Gilead Sciences, Inc. Cd73 compounds
CA3236564A1 (en) * 2021-11-02 2023-05-11 Visterra, Inc. Fc variants with abolished binding to fcgammar and c1q
WO2023088429A1 (zh) * 2021-11-19 2023-05-25 杭州尚健生物技术有限公司 SIRPα变体及其应用
CN118488946A (zh) 2021-12-22 2024-08-13 吉利德科学公司 Ikaros锌指家族降解剂及其用途
EP4452415B1 (en) 2021-12-22 2026-02-25 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
WO2023154578A1 (en) 2022-02-14 2023-08-17 Sana Biotechnology, Inc. Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
CA3253296A1 (en) 2022-03-17 2023-09-21 Gilead Sciences, Inc. Zinc Finger Degradation Agents of the Ikaros Family and Their Uses
WO2023183313A1 (en) 2022-03-22 2023-09-28 Sana Biotechnology, Inc. Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods
AU2023240346A1 (en) 2022-03-24 2024-09-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
TWI876305B (zh) 2022-04-05 2025-03-11 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
CA3247812A1 (en) * 2022-04-20 2023-10-26 Biosion Inc. Antibodies targeting Syrp-Alpha and their uses
WO2023205719A1 (en) 2022-04-21 2023-10-26 Gilead Sciences, Inc. Kras g12d modulating compounds
JP2025523369A (ja) 2022-06-01 2025-07-23 エーエルエックス オンコロジー インコーポレイテッド 尿路上皮癌腫を治療するための併用療法
US20240116928A1 (en) 2022-07-01 2024-04-11 Gilead Sciences, Inc. Cd73 compounds
WO2024064668A1 (en) 2022-09-21 2024-03-28 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
KR102584898B1 (ko) * 2022-10-24 2023-10-04 연세대학교 산학협력단 자궁내막암 진단 방법 및 이를 이용한 키트
EP4619435A1 (en) 2022-11-16 2025-09-24 Boehringer Ingelheim International GmbH Predictive efficacy biomarkers for anti-sirpa antibodies
WO2024125330A1 (en) * 2022-12-16 2024-06-20 Beijing Neox Biotech Limited ANTIBODIES AGAINST SIRPα AND USES THEREOF
WO2024125331A1 (en) * 2022-12-16 2024-06-20 Beijing Neox Biotech Limited ANTIBODIES AGAINST SIRPα AND USES THEREOF
EP4638436A1 (en) 2022-12-22 2025-10-29 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
CN118546255A (zh) * 2023-02-24 2024-08-27 恒翼生物医药(上海)股份有限公司 一种靶向αvβ3和CD47的双功能融合蛋白以及其应用
CN120882725A (zh) 2023-04-11 2025-10-31 吉利德科学公司 Kras调节化合物
WO2024220917A1 (en) 2023-04-21 2024-10-24 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20250042922A1 (en) 2023-06-30 2025-02-06 Gilead Sciences, Inc. Kras modulating compounds
AU2024297978A1 (en) 2023-07-26 2026-02-05 Gilead Sciences, Inc. Parp7 inhibitors
US20250066328A1 (en) 2023-07-26 2025-02-27 Gilead Sciences, Inc. Parp7 inhibitors
AU2024337913A1 (en) 2023-09-08 2026-03-26 Gilead Sciences, Inc. Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
WO2025054347A1 (en) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250154172A1 (en) 2023-11-03 2025-05-15 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
US20250376484A1 (en) 2024-05-21 2025-12-11 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2026039365A1 (en) 2024-08-12 2026-02-19 Gilead Sciences, Inc. Kras modulating compounds

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
AU632065B2 (en) 1988-09-23 1992-12-17 Novartis Vaccines And Diagnostics, Inc. Cell culture medium for enhanced cell growth, culture longevity and product expression
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
EP0656064B1 (en) 1992-08-17 1997-03-05 Genentech, Inc. Bispecific immunoadhesins
US5472556A (en) 1993-06-24 1995-12-05 Alfred D. Lobo Co. Flow-through linear transfer system for making a laminate from synthetic resinous sheets
FR2707446B1 (fr) 1993-07-07 1995-08-11 Pouyet Int Dispositif terminal d'interconnexion téléphonique d'abonné.
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
EP0914452A2 (en) 1996-06-17 1999-05-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Novel ptp20, pcp-2, bdp1, clk and sirp proteins and related products and methods
DE19782089T1 (de) 1996-10-29 1999-12-23 Univ Nebraska At Lincoln Linco Verfahren zum Nachweisen von Punktmutationen in DNA unter Verwendung von Fluoreszenzenergieübergang
US6143559A (en) 1996-11-18 2000-11-07 Arch Development Corporation Methods for the production of chicken monoclonal antibodies
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
GB9626026D0 (en) 1996-12-14 1997-01-29 Zeneca Ltd Chemical compounds
CA2226962A1 (en) 1998-02-16 1999-08-16 Marie Sarfati Use of binding agents to cd47 and its ligands in the treatment or the prophylaxis of various inflammatory, autoimmune and allergic diseases and in the treatment of graft rejection
EP1048299A1 (en) 1999-04-28 2000-11-02 Faculteit der Geneeskunde van de Vrije Universiteit Method for inhibiting cell functioning for use in anti-inflammatory and anti-tumour therapies
AU1701001A (en) * 1999-11-30 2001-06-12 Eberhard-Karls-Universitat Tubingen Universitatsklinikum Antibodies against signal regulator proteins
GB9930706D0 (en) 1999-12-24 2000-02-16 Medical Res Council Composition for inhibiting macrophage activity
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
AU2002315052A1 (en) 2001-05-15 2002-11-25 Emory University Polynucleotides and polypeptides relating to the modulation of sirp alpha-cd47
CA2513113A1 (en) 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
WO2005014653A2 (en) 2003-02-28 2005-02-17 Protein Design Labs, Inc. Humanized chicken antibodies
US20040213792A1 (en) 2003-04-24 2004-10-28 Clemmons David R. Method for inhibiting cellular activation by insulin-like growth factor-1
US20100215640A1 (en) 2003-04-24 2010-08-26 The University Of North Carolina At Chapel Hill Method for inhibiting cellular activation by insulin-like growth factor-1
US8613922B2 (en) 2003-04-24 2013-12-24 The University Of North Carolina At Chapel Hill Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP)
TW200902555A (en) 2005-01-03 2009-01-16 Hoffmann La Roche Antibodies against IL-13 receptor alpha 1 and uses thereof
EP2860192B1 (en) 2005-10-12 2017-09-27 MorphoSys AG Generation and profiling of fully human HuCAL GOLD-derived therapeutic antibodies specific for human CD38
US20100239578A1 (en) 2007-10-11 2010-09-23 University Health Network Modulation of sirp-alpha - cd47 interaction for increasing human hematopoietic stem cell engraftment and compounds therefor
CA2965198C (en) 2008-01-15 2021-02-16 The Board Of Trustees Of The Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
AU2009205665B2 (en) 2008-01-15 2013-12-05 The Board Of Trustees Of The Leland Stanford Junior University Methods for manipulating phagocytosis mediated by CD47
EP2271657B1 (en) 2008-03-04 2017-03-01 Crystal Bioscience Inc. Gel microdrop composition and method of using the same
EP2111869A1 (en) 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system
US8592644B2 (en) 2009-08-13 2013-11-26 Crystal Bioscience Inc. Transgenic animal for production of antibodies having minimal CDRS
WO2011041453A1 (en) 2009-09-29 2011-04-07 The Board Of Trustees Of The Leland Stanford Junior University Isolation and use of melanoma cancer stem cells
KR101658479B1 (ko) 2010-02-09 2016-09-21 삼성전자주식회사 불휘발성 메모리 장치, 그것의 동작 방법, 그리고 그것을 포함하는 메모리 시스템
EP2609194B1 (en) 2010-08-27 2019-01-16 University Health Network Methods for enriching pluripotent stem cell-derived cardiomyocyte progenitor cells and cardiomyocyte cells based on sirpa expression
CA2835222C (en) 2011-05-24 2020-08-25 Crystal Bioscience Inc. Transgenic chicken comprising an inactivated immunoglobulin gene
WO2013056352A1 (en) * 2011-10-19 2013-04-25 University Health Network Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers
US9394372B2 (en) 2011-10-21 2016-07-19 Crystal Bioscience Inc. In vivo method for generating diversity in a protein scaffold
EP4721752A2 (en) 2011-12-30 2026-04-08 Cellscript, Llc Herstellung und verwendung von in vitro-synthetisierter ssrna zur einführung in säugetierzellen zur induktion einer biologischen oder biochemischen wirkung
CA2887706C (en) 2012-11-05 2022-08-02 Regeneron Pharmaceuticals Genetically modified non-human animals and methods of use thereof
ES2914814T3 (es) 2012-12-17 2022-06-16 Pf Argentum Ip Holdings Llc Tratamiento de células enfermas CD47+ con fusiones SIRP Alfa-Fc
CA2900256C (en) 2013-02-05 2023-03-21 Kim J. HASENKRUG Cd47 targeted therapies for the treatment of infectious disease
PT2970493T (pt) 2013-03-15 2019-06-27 Univ Leland Stanford Junior Métodos para obter doses terapeuticamente eficazes de agentes anti-cd47
ES2898627T3 (es) 2013-04-29 2022-03-08 Univ Leland Stanford Junior Uso de agentes anti-CD47 para mejorar la inmunización
ES2765483T3 (es) 2013-09-18 2020-06-09 Univ Leland Stanford Junior Modulación de las vías de eferocitosis para el tratamiento de una enfermedad aterosclerótica
ES3012974T3 (en) 2014-01-08 2025-04-10 Univ Leland Stanford Junior Targeted therapy for lung cancer
AU2015229448B2 (en) * 2014-03-11 2020-09-03 The Board Of Trustees Of The Leland Stanford Junior University Anti SIRP-alpha antibodies and Bi-specific Macrophage Enhancing antibodies
TWI759810B (zh) 2014-08-08 2022-04-01 美商Ａｌｘ腫瘤技術股份有限公司 信號調節蛋白α(signal-regulatory proteinα, SIRP-α)變體構築物及其用途
HUE046661T2 (hu) 2014-08-15 2020-03-30 Merck Patent Gmbh SIRP-alfa immunglobulin fúziós proteinek
FI3656869T4 (fi) 2014-08-26 2025-06-04 Univ Leland Stanford Junior Kantasolujen siirrostaminen kantasoluihin kohdentuvan aineen ja immunoregulatorista signaalia moduloivan aineen yhdistelmän kanssa
EP3012271A1 (en) 2014-10-24 2016-04-27 Effimune Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases
EP3209769B1 (en) 2014-10-24 2020-08-05 The Board of Trustees of the Leland Stanford Junior University Compositions and methods for inducing phagocytosis of mhc class i positive cells and countering anti-cd47/sirpa resistance
EP3247464B1 (en) 2015-01-21 2019-09-18 The Board of Trustees of the Leland Stanford Junior University Use of tlr agonist and anti-cd47 agent to enhance phagocytosis of cancer cells
US10618976B2 (en) 2015-06-16 2020-04-14 The Board Of Trustees Of The Leland Stanford Junior University SIRP-α agonist antibody
RU2766690C2 (ru) 2015-07-28 2022-03-15 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Модифицированные моноциты/макрофаги, экспрессирующие химерные антигенные рецепторы, и их применения
EP3341015B2 (en) 2015-08-26 2023-12-27 The Board of Trustees of the Leland Stanford Junior University Enhanced depletion of targeted cells with cd47 blockade and an immune costimulatory agonist
JP7078533B2 (ja) 2015-10-21 2022-05-31 オーエスイー イムノセラピューティクス 炎症促進性細胞へのマクロファージ分極を改変して癌を治療するための抗ＳＩＲＰａ化合物
US10946042B2 (en) 2015-12-01 2021-03-16 The Trustees Of The University Of Pennsylvania Compositions and methods for selective phagocytosis of human cancer cells
AU2016365829B2 (en) 2015-12-11 2020-02-06 The Board Of Trustees Of The Leland Stanford Junior University Treatment of cancer with dual targeting of CD47 and EGFR
EP3442541B1 (en) 2016-04-10 2021-11-17 Georgia State University Research Foundation, Inc. Composition for use in treating cancer
RS66062B1 (sr) 2016-04-14 2024-11-29 Ose Immunotherapeutics Nova anti-sirpa antitela i njihove terapijske primene
SG11201808465UA (en) 2016-04-14 2018-10-30 Ose Immunotherapeutics NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS
US20190153095A1 (en) 2016-07-05 2019-05-23 National University Corporation Kobe University Antitumor Agent
KR102878970B1 (ko) 2016-08-03 2025-10-30 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 항-SIRPalpha 항체 요법의 대식세포 증진 효능에서 Fc 수용체 참여의 붕괴
JOP20190009A1 (ar) 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
CN118027200A (zh) 2016-12-09 2024-05-14 艾利妥 抗SIRPα抗体及其使用方法
JP7321934B2 (ja) 2017-01-30 2023-08-07 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 幹細胞移植のための非遺伝毒性移植前処置レジメン
CN118267470A (zh) 2017-04-13 2024-07-02 赛罗帕私人有限公司 抗SIRPα抗体
CN118271443A (zh) 2017-05-16 2024-07-02 拜奥迪斯私人有限公司 抗SIRPα抗体
WO2019023347A1 (en) 2017-07-26 2019-01-31 Forty Seven, Inc. ANTI-SIRP-ALPHA ANTIBODIES AND ASSOCIATED METHODS
MX2020009774A (es) 2018-03-21 2020-10-08 Alx Oncology Inc Anticuerpos contra proteína alfa reguladora de señal y métodos de uso.
EP3802602A1 (en) 2018-05-25 2021-04-14 Alector LLC Anti-sirpa antibodies and methods of use thereof
KR20250079073A (ko) 2018-07-10 2025-06-04 고쿠리츠다이가쿠호진 고베다이가쿠 항 SIRPα 항체
US11591390B2 (en) 2018-09-27 2023-02-28 Celgene Corporation SIRP-α binding proteins and methods of use thereof
EP3880239A4 (en) 2018-11-14 2022-11-23 Arch Oncology, Inc. THERAPEUTIC SIRPalpha ANTIBODIES
CA3118966A1 (en) 2018-11-15 2020-05-22 Byondis B.V. Humanized anti-sirpa antibodies

Also Published As

Publication number Publication date
GEAP202215050A (en) 2022-11-10
US20220002434A1 (en) 2022-01-06
US20210363269A1 (en) 2021-11-25
PL3515490T3 (pl) 2022-12-19
US20260001960A1 (en) 2026-01-01
JP2024153615A (ja) 2024-10-29
CN117756937A (zh) 2024-03-26
HUE060170T2 (hu) 2023-02-28
IL265439B1 (en) 2024-04-01
JP7181874B2 (ja) 2022-12-01
JP7508425B2 (ja) 2024-07-01
CL2021000704A1 (es) 2021-07-30
US20180105600A1 (en) 2018-04-19
US11401338B2 (en) 2022-08-02
CN109862915A (zh) 2019-06-07
IL265439B2 (en) 2024-08-01
IL265439A (en) 2019-05-30
EP4119580B1 (en) 2025-11-05
JP2022003031A (ja) 2022-01-11
IL297891B1 (en) 2024-04-01
EP3515490A1 (en) 2019-07-31
EP3515490B8 (en) 2022-09-14
CO2019003809A2 (es) 2019-04-30
RS63658B1 (sr) 2022-11-30
WO2018057669A1 (en) 2018-03-29
US20230018821A1 (en) 2023-01-19
GEAP202315361A (en) 2023-04-25
BR112019003027A2 (pt) 2019-05-14
ZA201900937B (en) 2023-05-31
CN109862915B (zh) 2023-12-12
EP3515490B1 (en) 2022-08-10
GEP20237528B (en) 2023-08-10
NZ750161A (en) 2025-08-29
PH12019500600A1 (en) 2019-06-03
RU2019111888A3 (https=) 2020-10-22
IL297891B2 (en) 2024-08-01
PE20190575A1 (es) 2019-04-22
SMT202200426T1 (it) 2022-11-18
GEP20237480B (en) 2023-03-27
US11242404B2 (en) 2022-02-08
MA46290A (fr) 2019-07-31
JOP20190009A1 (ar) 2019-01-27
RU2019111888A (ru) 2020-10-22
PT3515490T (pt) 2022-10-18
KR20190052100A (ko) 2019-05-15
CA3034480A1 (en) 2018-03-29
EP4119580A1 (en) 2023-01-18
AU2017332285B2 (en) 2024-07-04
SG10201912878UA (en) 2020-02-27
AU2017332285A1 (en) 2019-02-14
CN117946268A (zh) 2024-04-30
MX2019003168A (es) 2019-06-10
DK3515490T3 (da) 2022-10-24
US12404340B2 (en) 2025-09-02
SA519401371B1 (ar) 2022-12-04
UA126281C2 (uk) 2022-09-14
KR102601298B1 (ko) 2023-11-15
MY197854A (en) 2023-07-20
EP3515490A4 (en) 2020-04-29
LT3515490T (lt) 2022-11-10
CL2019000668A1 (es) 2019-05-31
HRP20221323T1 (hr) 2022-12-23
IL297891A (en) 2023-01-01
ES2932602T3 (es) 2023-01-23
JP2020503057A (ja) 2020-01-30

Similar Documents

Publication Publication Date Title
IL265439A (en) Antibodies against signal-regulatory alpha protein and methods of use
IL277337A (en) Antibodies against alpha signal modulatory protein and methods of use
IL308156B1 (en) Anti-C1S antibodies and methods of using them
IL265800A (en) Anti-lag-3 antibodies and methods of using them
ZA201906730B (en) Anti-trem2 antibodies and methods of use thereof
ZA202003695B (en) Anti-neuropilin antigen-binding proteins and methods of use thereof
SG10201912879YA (en) Anti-sirp-alpha antibodies and methods of use thereof
PL3618863T3 (pl) Przeciwciała anty- tigit i sposoby ich zastosowania
SG10201912563XA (en) Anti-tim-3 antibodies and methods of use thereof
IL259495A (en) Antibodies and methods for using them
IL254887A0 (en) Anti-sortilin antibodies and methods of using them
IL270793A (en) Anti-HTRA1 antibodies and methods of using them
IL274221A (en) Antibodies to ANTI-APOC3 and methods of use
ZA202002144B (en) Antibodies and methods of use
HK40046121A (en) Antibodies against signal-regulatory protein alpha and methods of use